Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Total Non-Current Liabilities (2016 - 2022)

Cardiff Oncology's Total Non-Current Liabilities history spans 12 years, with the latest figure at $9.8 million for Q4 2022.

  • For Q4 2022, Total Non-Current Liabilities rose 7.9% year-over-year to $9.8 million; the TTM value through Dec 2022 reached $9.8 million, up 7.9%, while the annual FY2022 figure was $9.8 million, 7.9% up from the prior year.
  • Total Non-Current Liabilities for Q4 2022 was $9.8 million at Cardiff Oncology, up from $9.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $9.8 million in Q4 2022 and bottomed at $3.9 million in Q3 2018.
  • The 5-year median for Total Non-Current Liabilities is $5.7 million (2020), against an average of $5.9 million.
  • The largest annual shift saw Total Non-Current Liabilities tumbled 78.44% in 2018 before it soared 45.24% in 2021.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $4.1 million in 2018, then soared by 42.29% to $5.8 million in 2019, then grew by 8.89% to $6.3 million in 2020, then skyrocketed by 45.24% to $9.1 million in 2021, then rose by 7.9% to $9.8 million in 2022.
  • Per Business Quant, the three most recent readings for CRDF's Total Non-Current Liabilities are $9.8 million (Q4 2022), $9.1 million (Q4 2021), and $7.8 million (Q3 2021).